175 related articles for article (PubMed ID: 7339821)
1. Sulfonamide activity against Mycobacterium fortuitum and Mycobacterium chelonei.
Wallace RJ; Jones DB; Wiss K
Rev Infect Dis; 1981; 3(5):898-904. PubMed ID: 7339821
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of trimethoprim and sulfamethoxazole against the nontuberculous mycobacteria.
Wallace RJ; Wiss K; Bushby MB; Hollowell DC
Rev Infect Dis; 1982; 4(2):326-31. PubMed ID: 7111959
[TBL] [Abstract][Full Text] [Related]
3. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities.
Wallace RJ; Swenson JM; Silcox VA; Bullen MG
J Infect Dis; 1985 Sep; 152(3):500-14. PubMed ID: 3875667
[TBL] [Abstract][Full Text] [Related]
4. Agar disk elution method for susceptibility testing of Mycobacterium marinum and Mycobacterium fortuitum complex to sulfonamides and antibiotics.
Stone MS; Wallace RJ; Swenson JM; Thornsberry C; Christensen LA
Antimicrob Agents Chemother; 1983 Oct; 24(4):486-93. PubMed ID: 6651277
[TBL] [Abstract][Full Text] [Related]
5. Disk diffusion testing of susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to antibacterial agents.
Wallace RJ; Dalovisio JR; Pankey GA
Antimicrob Agents Chemother; 1979 Nov; 16(5):611-4. PubMed ID: 526002
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to cefmetazole.
Casal MJ; Rodriguez FC; Benavente MC
Antimicrob Agents Chemother; 1985 Feb; 27(2):282-3. PubMed ID: 3857020
[TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibility of Mycobacterium fortuitum to non-antituberculous antibacterial agents.
Casal MJ; Rodriguez FC
Ann Microbiol (Paris); 1983; 134A(1):73-8. PubMed ID: 6847037
[TBL] [Abstract][Full Text] [Related]
8. Mutational resistance as the mechanism of acquired drug resistance to aminoglycosides and antibacterial agents in Mycobacterium fortuitum and Mycobacterium chelonei. Evidence is based on plasmid analysis, mutational frequencies, and aminoglycoside-modifying enzyme assays.
Wallace RJ; Hull SI; Bobey DG; Price KE; Swenson JM; Steele LC; Christensen L
Am Rev Respir Dis; 1985 Aug; 132(2):409-16. PubMed ID: 4026065
[TBL] [Abstract][Full Text] [Related]
9. Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth microdilution.
Swenson JM; Thornsberry C; Silcox VA
Antimicrob Agents Chemother; 1982 Aug; 22(2):186-92. PubMed ID: 6927280
[TBL] [Abstract][Full Text] [Related]
10. Disseminated Mycobacterium chelonei infection: response to sulfonamides.
Tice AD; Solomon RJ
Am Rev Respir Dis; 1979 Jul; 120(1):197-201. PubMed ID: 464378
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.
Heidarieh P; Mirsaeidi M; Hashemzadeh M; Feizabadi MM; Bostanabad SZ; Nobar MG; Hashemi Shahraki A
Microb Drug Resist; 2016 Mar; 22(2):172-8. PubMed ID: 26468990
[TBL] [Abstract][Full Text] [Related]
12. Differentiation of Mycobacterium chelonei from M. fortuitum by ciprofloxacin susceptibility.
Collins CH; Yates MD; Uttley AH
J Hyg (Lond); 1985 Dec; 95(3):619-21. PubMed ID: 2936800
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae.
Swenson JM; Wallace RJ; Silcox VA; Thornsberry C
Antimicrob Agents Chemother; 1985 Dec; 28(6):807-11. PubMed ID: 4083863
[TBL] [Abstract][Full Text] [Related]
14. Etest for routine clinical antimicrobial susceptibility testing of rapid-growing mycobacteria isolates.
Koontz FP; Erwin ME; Barrett MS; Jones RN
Diagn Microbiol Infect Dis; 1994 Jul; 19(3):183-6. PubMed ID: 7821001
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility of Mycobacterium marinum to dihydromycoplanecin A and ten other antimicrobial agents.
Arai H; Nakajima H; Kaminaga Y
J Dermatol; 1990 Jun; 17(6):370-4. PubMed ID: 2384640
[TBL] [Abstract][Full Text] [Related]
16. Clinical usefulness of amikacin and doxycycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonei.
Dalovisio JR; Pankey GA; Wallace RJ; Jones DB
Rev Infect Dis; 1981; 3(5):1068-74. PubMed ID: 7339806
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium avium, Mycobacterium fortuitum, and Mycobacterium chelonae to ticarcillin in combination with clavulanic acid.
Casal MJ; Rodriguez FC; Luna MD; Benavente MC
Antimicrob Agents Chemother; 1987 Jan; 31(1):132-3. PubMed ID: 3105441
[TBL] [Abstract][Full Text] [Related]
18. Growth of group IV mycobacteria on medium containing various saturated and unsaturated fatty acids.
Saito H; Tomioka H; Yoneyama T
Antimicrob Agents Chemother; 1984 Aug; 26(2):164-9. PubMed ID: 6486760
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptiiblity of Mycobacterium fortuitum and Mycobacterium chelonei to amikacin.
Dalovisio JR; Pankey GA
J Infect Dis; 1978 Mar; 137(3):318-21. PubMed ID: 632627
[TBL] [Abstract][Full Text] [Related]
20. Spectrum of drugs against atypical mycobacteria: how valid is the current practice of drug susceptibility testing and the choice of drugs?
Rastogi N; Goh KS; Guillou N; Labrousse V
Zentralbl Bakteriol; 1992 Dec; 277(4):474-84. PubMed ID: 1303690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
